Become A Featured Company

Who is Focused on the Huge Opportunity in Medical Cannabis?

Robin Lefferts

October 18th, 2018

Exclusive, News, Top Story

With California’s adult-use legalization fresh in investors’ minds, and full legalization happening in Canada, much of the focus has been around the retail potential of cannabis and related products. That is quite a change from even a couple of years ago, when the disruptive potential of medical marijuana was the biggest topic. In the intervening time, nothing has diminished the potential of medical cannabis but the headlines have moved to beverages and retail distribution. It may be worth another look to see what companies are executing in the medical arena.

One such player is Empower Clinics (CSE: EPW). The company currently owns physician-staffed clinics in Oregon, Washington, and Illinois, providing expert medical care to more than 25,000 registered patients across its network. Empower is capitalizing on a vacuum in the medical industry, where patients are increasingly seeking less harmful alternatives to currently prescribed treatments like opioids while traditionally-trained doctors lack the necessary training or comfort level to prescribe medical cannabis. Empower Clinics offer the type of care and expertise that is often lacking for patients interested in cannabis, many of whom turn to their local budtenders or the Internet for treatment advice due to a lack of valid medical opinions.

Empower’s Medical Clinic Model

Specialized clinics are increasingly popular throughout North America. Pain clinics, sleep clinics, cancer clinics… the biggest and most common indications spur the development of clinics to specifically address those conditions. Empower is turning that approach sideways a bit, offering specialized medical cannabis clinics that can help patients with a variety of indications rather than focusing on one condition. But the effect is similar. Just as someone with chronic pain may turn to a specialist after striking out with the family physician, a patient interested in cannabis as an alternative therapy may turn to doctors with expertise in the field rather than relying on the family physician who may be uncomfortable with or simply unaware of the therapeutic uses for cannabis.

A study of 926 Washington cancer patients shows that 74% wanted information on cannabis from their cancer providers, but less than 15% received information from their physician or nurse. Most received information from friends, family, websites, articles, or other cancer patients. Statistics like this justify Empower’s approach to offering expert medical cannabis advice from physicians.

The model has been proven in Oregon, where Empower Clinics has issued more than 30% of the state’s medical cannabis cards. Seeing the success there, Empower expanded into Washington where it has 9 clinics. Empower recently opened a clinic in downtown Chicago, and Illinois is a very interesting market. In the first three years of the state’s medical marijuana program, through September 2017, the Department of Public Health approved 24,000 patients. In the year since, that number has nearly doubled to 44,000 patients with no sign of slowing.

In late August, Illinois Governor Bruce Rauner signed into law a bill that made it easier to get a medical cannabis card in a number of ways. The headliner was the fact that the law made it easier to prescribe cannabis as an alternative to opioids for the treatment of pain. Everybody is aware of the epidemic of opioid abuse, and Illinois has chosen to directly address the problem by encouraging the use of cannabis as a substitute. Empower plans to explore further expansion in the state.

Parallel Product Development and Distribution

Medical cannabis users often, for understandable reasons related to health, would prefer to not smoke the flower if at all possible. Alternative delivery methods, like tinctures or topical creams, are gaining market share as the science of cannabinoid delivery catches up following years of research prohibition. Empower recognizes the demand for these types of products and has developed its own line of non-THC, hemp-derived CBD products. The company’s Sollievo line of CBD products is expected to launch nationally soon, as the CBD products are legal throughout the United States.

Empower is also developing similar cannabinoid-based products for a variety of the most common indications, like sleep, pain, stress and digestion. The company plans to leverage its own client base while also distributing outside of its own network of clinics, providing the potential for a significantly wider revenue stream.

In the meantime, Empower signed a distribution agreement with Integrated Cannabis Company to distribute ICC’s CBD-infused X-SPRAYS™ line of products to Empower patients. The sprays are intended to support sleep, libido, energy and recovery. Deals like this provide Empower another source of potential revenue while expanding the treatments available to its ever expanding roster of patients.

Looking Ahead

Empower Clinics is undertaking a two-pronged strategy to address the shortage of trusted expertise in the medical cannabis market. Expansion of its proven clinic model, along with development and distribution of specialized cannabis-based treatments, is ramping up and should continue over the coming quarters. As the level of scientific cannabis research explodes and the political environment surrounding the plant softens, Empower’s position as an early mover in key markets could prove beneficial for the company as it seeks to stay ahead of the medical cannabis curve.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading